Pendopharm https://pendopharm.com/ Fri, 27 Feb 2026 20:46:19 +0000 en-CA hourly 1 https://wordpress.org/?v=6.9 Pendopharm announces the commercialization of Buccolam® in Canada https://pendopharm.com/news/pendopharm-announces-the-commercialization-of-buccolam-in-canada/ Fri, 27 Feb 2026 20:45:07 +0000 https://pendopharm.com/?p=2018 MONTREAL, Canada, February 27, 2026 – Pendopharm, a division of Pharmascience Inc. (Pendopharm), is pleased to announce that Buccolam®is now available in…

The post Pendopharm announces the commercialization of Buccolam® in Canada appeared first on Pendopharm.

]]> Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults. https://pendopharm.com/news/pendopharm-announces-the-approval-of-yorvipath-palopegteriparatide-injection-for-the-treatment-of-chronic-hypoparathyroidism-in-adults/ Fri, 06 Feb 2026 18:26:48 +0000 https://pendopharm.com/?p=2002 Montreal, February 6, 2026 – Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for…

The post Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults. appeared first on Pendopharm.

]]> Pendopharm® signs an exclusive distribution agreement with Neuraxpharm for T\CBuccolam® in Canada and announces its authorization by Health Canada. https://pendopharm.com/news/pendopharmmd-signe-un-accord-de-distribution-exclusif-avec-neuraxpharm-pour-prbuccolammd-au-canada-et-annonce-son-approbation-par-sante-canada/ Mon, 04 Aug 2025 15:09:42 +0000 https://pendopharm.com/?p=1900 MONTREAL, Canada, August 4th, 2025 – Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has entered into an…

The post Pendopharm® signs an exclusive distribution agreement with Neuraxpharm for T\CBuccolam® in Canada and announces its authorization by Health Canada. appeared first on Pendopharm.

]]> Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada https://pendopharm.com/news/pendopharm-and-kalvista-partner-to-bring-first-oral-on-demand-hae-treatment-to-canada/ Thu, 26 Jun 2025 21:21:11 +0000 https://pendopharm.com/?p=1875 Montreal, June 26th, 2025 – Pendopharm®, a division of Pharmascience Inc., has entered into an exclusive distribution agreement with KalVista Pharmaceuticals,…

The post Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada appeared first on Pendopharm.

]]> Pendopharm announces public drug coverage plan listings for Octasa® (oral mesalamine)   https://pendopharm.com/news/pendopharm-announces-public-drug-coverage-plan-listings-for-octasa-oral-mesalamine/ Mon, 09 Sep 2024 17:00:00 +0000 https://pendopharm.com/?p=1814 MONTREAL, Canada, September 9th, 2024 – Pendopharm, a division of Pharmascience Inc., is pleased to announce that Octasa® 800 mg and Octasa®…

The post Pendopharm announces public drug coverage plan listings for Octasa® (oral mesalamine)   appeared first on Pendopharm.

]]>